Overview
| Screening/Lead Optimization | Pre-clinic | Phase I | Phase IIa | Phase IIb | Phase III | Indication |
|---|---|---|---|---|---|---|
Naltrexone Depot |
Alcohol dependence | |||||
| ELB353 |
Chronic inflammation | |||||
| PDE10** |
CNS | |||||
| elbHCV* |
HCV | |||||
| Buprenorphine Depot |
Opiate Addiction | |||||
| Other targets |
CNS / Inflammation Immunology | |||||
* Partner: Gilead
** Partner: Wyeth
